Articles tagged with Renal Failure
Researchers successfully generated rat-derived kidneys in mice using interspecies blastocyst complementation, demonstrating potential for growing transplantable human organs in larger animals. The study represents an important step toward addressing global kidney shortages.
LRBA deficiency, a rare inherited condition, impairs kidney function by disrupting water and sodium balance, leading to polyuria and electrolyte abnormalities. Treatment with desmopressin may help manage excessive urination in some patients.
Recent studies show finerenone preserves kidney function, reduces cardiovascular risk and improves survival across a broader range of CKD patients. Finerenone also reduces kidney failure, heart failure or cardiovascular death risk by 23-24% in non-diabetic patients.
In an exploratory analysis, finerenone was found to slow kidney function decline, reduce albuminuria, and lower the risk of kidney failure or substantial loss of kidney function in patients with glomerular diseases. These findings suggest a crucial role for finerenone in preserving kidney function in this population.
In a large study of 1,584 adults with chronic kidney disease, finerenone was shown to significantly slow the decline in kidney function compared to placebo. The drug also reduced cardiovascular disease risk and protein excretion in urine by over 40%.
Adults with lower measured glomerular filtration rates had a higher risk of all-cause mortality, kidney failure, and major adverse cardiovascular events. Lower GFR values were also associated with increased hospitalization for heart failure and acute kidney injury.
A pioneering clinical trial demonstrates CAR T cells can safely desensitize highly sensitized patients, making kidney transplantation possible. Two patients with end-stage kidney disease successfully received kidney transplants after years of waiting.
Dogs with lower urine ammonia-to-creatinine ratios may experience faster kidney disease progression, higher fatality rates, and shorter survival times. UACR levels also may represent an earlier marker of acid dysregulation before more obvious changes in blood tests.
International experts in laboratory medicine, osteoporosis, and chronic kidney disease recommend ending routine reporting of albumin-adjusted ('corrected') calcium. The practice may misclassify patients and compromise care due to unreliable correction formulas and variability in local measurements.
A Brown University study found that expanded Medicaid coverage significantly improves one-year mortality rates for young adults with kidney failure. The researchers discovered improvements in pre-dialysis care, increased use of dialysis, and longer dialysis sessions, all leading to better long-term health outcomes.
Researchers at Penn Medicine have identified a previously unrecognized form of diabetic kidney disease marked by clusters of immune cells, specifically B cells, that are linked to faster disease progression. The study's findings could guide more targeted treatments in the future.
Researchers found a clear connection between oral health and kidney health, with immune dysregulation and systemic inflammation driving the relationship. The study highlights the need for physicians to integrate oral and renal health into clinical care systems.
Researchers discovered VISTA as a critical immune checkpoint that balances immune activation and inflammation resolution during kidney injury. Administering exogenous VISTA protein shows potent protection against acute kidney injury and its progression to chronic disease.
Researchers found that an imbalanced gut microbiome escalates the production of metabolic byproducts, driving a feedback loop that worsens CKD. Blocking a single enzyme in the gut stopped this cycle, suggesting iNOS as a potential target for treatment.
A nationwide intervention has led to increased kidney transplants among Black patients, with a 5.3 transplant increase per 1,000 listings. The study found that wait time modifications, required by a national policy, resulted in a 1.7-year gain in priority status for Black candidates.
A study found that COVID-19 infection significantly increases the risk of acute kidney injury, chronic kidney disease, and kidney failure in US adults. The research used machine learning models to analyze data from over three million patients, revealing a 2.3-times higher risk of acute kidney injury compared to influenza.
The ESE and ESPE have launched a landmark Joint Clinical Practice Guidance to support structured and effective transition of young people with endocrine conditions. The Guidance provides practical, evidence-based recommendations to ensure continuity, safety and quality of care during this critical phase in a patient's life.
Vertebral fractures are a devastating complication of advanced kidney disease, associated with increased risk of further fractures and cardiovascular events. The first global consensus statement offers practical recommendations for clinicians to identify and manage vertebral fractures in patients with chronic kidney disease stages G4–G5D.
A large-scale study found that adhering to the EAT–Lancet planetary health diet was significantly associated with a reduced risk of incident CKD. The diet emphasizes fruits, vegetables, legumes, and limited consumption of added sugars and fats.
Salk Institute scientists discover that dietary supplementation of the amino acid methionine protects infected mice against inflammation-related wasting, blood-brain barrier dysfunction, and death. Methionine boosts kidney filtration, reducing circulating cytokine levels and improving disease outcomes.
The study found that even with immunosuppressants, innate immunity remains activated, indicating a need for new therapies to prevent organ rejection. Researchers recommend combining therapies targeting innate immunity with advanced genetic engineering in donor pigs.
Early recognition of cast nephropathy through novel biomarkers can guide timely treatment, while tailored extracorporeal therapies show promise in preventing irreversible kidney damage. The review emphasizes the need for standardized biomarker-guided pathways and multicenter trials to advance personalized kidney support.
Researchers from Institute of Science Tokyo developed 'tubuloids' to capture the slow progression of chronic kidney disease (CKD), replicating key features such as DNA damage, cellular senescence, inflammation, and fibrosis. This realistic platform provides a new way to develop and test treatments for millions globally.
Researchers from the University of Missouri-Columbia have identified several genes that may be potential therapeutic targets for Chronic Kidney Disease (CKD) by regulating gene activity. These genes are involved in the signs of kidney damage, including fibrosis and inflammation.
Researchers at the University of Iowa Health Care have developed a new class of medication, pegcetacoplan, which directly targets the root cause of C3 glomerulopathy, a rare and severe kidney disease. The treatment has shown significant results, with up to 67% of children achieving complete remission and stabilization of kidney function.
Researchers review current evidence on extracellular vesicles' interaction with renal tubular epithelial cells, showing protective effects against damaged tubular cells. However, challenges remain to overcome, such as biodistribution and targeting issues.
The book covers genetic, epigenetic, and molecular foundations of renal dysfunction, as well as microbiota, immune interactions, and nephrotoxicity. It also highlights novel therapies and precision medicine approaches for better diagnostic and treatment strategies.
Researchers used human-induced pluripotent stem cell-derived kidney organoids to model nephronophthisis, revealing the Hippo signaling pathway's role in fibrosis. Inhibiting this pathway with drugs like verteporfin shows promise as a treatment option.
Researchers have made breakthroughs in overcoming immune reactions behind human rejection of transplanted pig kidneys, paving the way for more successful clinical trials. The study reveals three major immune responses against the pig kidney and identifies potential biomarkers as early-warning systems for rejection.
Researchers at University of Utah Health have found that AKI is triggered by ceramides, which cause serious injury by damaging kidney mitochondria. Using a backup drug candidate, the team was able to preserve mitochondrial integrity and prevent kidney injury in mice.
A recent FAU Engineering study leverages quantum computing to enhance the accuracy of chronic kidney disease (CKD) diagnosis. The research team developed and compared two automated systems: Classical Support Vector Machine (CSVM) and Quantum Support Vector Machine (QSVM). CSVM achieved remarkable 98.75% accuracy, while QSVM reached 87....
A culturally tailored community health worker intervention modestly lowered interdialytic weight gain and improved dialysis adherence among Hispanic and Latino patients with hemodialysis-dependent kidney failure. This study suggests that such interventions can enhance patient outcomes for these vulnerable populations.
A new study reveals that a large gap between two common kidney function tests may indicate future disease, particularly among older adults. The research found that over a third of hospitalized participants had a significant difference in their creatinine and cystatin C readings, which can predict serious health problems.
The navigate-kidney study finds that community health workers enhance holistic, patient-centered care through improved patient engagement and emotional wellbeing. This integration into dialysis care teams may lead to better outcomes for patients with kidney failure.
The study found CKD affects nearly 800 million worldwide, with diabetes and high blood pressure driving the greatest loss of healthy years. Access to kidney replacement therapies remains limited, highlighting the need for preventive measures and equitable care.
A study published in JAMA finds that using different methods to estimate glomerular filtration rate (eGFR) can lead to significant discrepancies, particularly for those with chronic kidney disease. The findings suggest that cystatin C-based eGFR may be more accurate in predicting clinical outcomes.
A comprehensive analysis of 70,000 participants across 10 trials found that SGLT2 inhibitors reduced the risk of chronic kidney disease (CKD) progression by 38% and slowed eGFR decline by 51%. The treatment was beneficial for all levels of kidney function and albuminuria levels, particularly in reducing hospitalizations.
The study suggests that SGLT2 inhibitors can benefit patients with varying levels of kidney function and albuminuria. Routine use of these medications may lead to improved kidney outcomes across different patient groups.
Researchers found that transferring patients to outpatient centers with minimal monitoring allowed more patients to recover kidney function and discontinue dialysis. The study, led by UC San Francisco, suggests a safer approach to weaning patients off dialysis without sacrificing recovery rates.
A team of researchers from Aarhus University has discovered a protein called VCAM1 that can predict whether kidney cells will survive or die after acute injury. The finding could lead to the development of targeted treatments and benefit millions of patients worldwide.
Researchers developed a scalable method to produce human kidney organoids, combining them with pig kidneys outside the body for transplantation. The transplanted organs functioned normally and showed no signs of damage or toxicity.
Researchers identified C-C chemokine ligand 5 (CCL5) as a key player in kidney injury and repair, with the molecule behaving both protectively and harmfully. The study suggests future drugs could target only its damaging effects, paving the way for more precise treatments for chronic kidney disease.
This study found that GLP-1RAs and SGLT2is offer the greatest cardiovascular benefits for adults with type 2 diabetes. The magnitude of benefit depends on baseline age, atherosclerotic cardiovascular disease, heart failure, and kidney impairment.
A simple blood test is being developed to detect acute kidney injury hours faster, allowing for earlier intervention and better management of chronic kidney disease. The test uses patented DNA aptamers to directly investigate structural kidney damage.
A new study found that AI tool accurately captures details in just three minutes from a body scan, highlighting the potential of using AI to repurpose data from routine scans. Visceral adipose tissue volume and fat deposits in muscle are strongly associated with diabetes and cardiovascular disease risk.
A USC Stem Cell-led team has successfully generated lab-grown kidney structures, or organoids, that exhibit kidney-like functions such as blood filtration and urine production. The 'assembloids' achieved maturity levels comparable to newborn mouse kidneys, paving the way for developing new therapies for patients awaiting transplant.
Researchers used AI models with integrated clinical and claims data to predict chronic kidney disease (CKD) progression to end-stage renal disease (ESRD). The study found that the models outperformed single data source models and reduced racial bias. The findings can inform likelihood and management of CKD, supporting targeted interven...
A novel drug target, CD300a, has been identified to suppress immune cell activation and prevent chronic heart and kidney failure after acute tissue injury. The treatment preserves cardiac function and reduces renal fibrosis in mice with genetic deficiency of CD300a.
Researchers developed a serum proteomics-based prediction model to identify biomarkers involved in ADPKD progression. The study identified 29 proteins linked to immune system, fat transport, and metabolism, which can predict kidney function decline rate. This breakthrough could lead to more accurate and earlier diagnosis of ADPKD.
Researchers identified a protective RNA molecule that regulates autophagic flux and protects against cellular injury, inflammation, and fibrosis in kidney cells. Boosting this tRNA-Asp-GTC-3'tDR increases kidney protection with less scarring, inflammation, and injury.
A pilot clinical trial has been initiated to test the efficacy of alpelisib in treating Dent disease 2, a rare genetic disorder affecting kidney function. The trial aims to improve abnormal kidney function and potentially provide a breakthrough treatment for patients with life-threatening complications.
A novel model reveals that local Ang II regulation plays a crucial role in maintaining kidney function balance. The study found that damaged kidneys compensate for the loss of function by increasing blood pressure and reducing glomerular atrophy.
QUT researchers create novel composite traits from UK Biobank data, identifying 50,000 biomarkers that outperform eGFR in detecting CKD. Their approach uncovers genetic signals missed by traditional methods.
Long-term data from the Phase 1/2 study of zigakibart demonstrate sustained proteinuria remission, stable kidney function, and a reassuring safety profile in patients with IgA nephropathy. The treatment also led to reductions in serum immunoglobulins, consistent with APRIL pathway inhibition.
Researchers at CRCHUM have discovered a crucial biomarker, miR-423-5p microRNA, to predict kidney function and diagnose chronic renal failure. The breakthrough could lead to early diagnosis, targeted approaches, and improved treatment options for millions of patients worldwide.
Surgeons at Mount Sinai performed the world's first heart-liver-kidney triple organ transplants in New York State, with two patients making full recoveries after the surgeries. The procedures were led by Anelechi Anyanwu and Sander S. Florman and represent a significant milestone in complex organ transplantation.
Researchers have identified a potential precision medicine approach to prevent chronic kidney disease progression by targeting type 5 collagen, a minor component of scar tissue. A repurposed anti-cancer drug, Cilengitide, has been shown to slow kidney scarring and disease progression in high-risk individuals.